Spots Global Cancer Trial Database for Niclosamide in Pediatric Patients With Relapsed and Refractory AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Official Title: Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML
Study ID: NCT05188170
Conditions
Interventions
Study Description
Brief Summary: Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Detailed Description:
Keywords
Eligibility
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University, Palo Alto, California, United States
Contact Details
Name: Kathleen M Sakamoto, MD, PhD
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
